The GHS-R1a agonist, LY444711, improved spatial memory performance in the APPSwDI mouse model of AD without altering glucose metabolism [72], suggesting that this treatment may be well tolerated in AD patients, who often present with impaired glucose metabolism [74]. The gene discussed is GHSR; the disease is Alzheimer disease.